IDEXX Laboratories has the GF Score of 96, which implies that the company
might have
Highest outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes IDEXX Laboratories
might have
Highest outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
IDEXX Laboratories GF Score Related Terms
XTER:IX1 vs A, WAT, NTRA: GF Score Comparison
For the Diagnostics & Research subindustry, IDEXX Laboratories's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories GF Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's GF Score distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's GF Score falls into.
IDEXX Laboratories (XTER:IX1) has a GF Score of 96 as of Jun. 25, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on IDEXX Laboratories and its competitors. This is near median its historical median of 93.00. Over the past decade, IDEXX Laboratories' GF Score has ranged from 71.00 to 100.00.
Is IDEXX Laboratories' GF Score too high?
IDEXX Laboratories' current GF Score of 96 is near median its 10-year median of 93.00. Over the past 10 years, this metric has ranged from a low of 71.00 to a high of 100.00. Overall, IDEXX Laboratories has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' GF Score compare to A and WAT?
IDEXX Laboratories' GF Score of 96 can be compared against companies in the Medical Diagnostics & Research industry. Historically, IDEXX Laboratories' own GF Score has ranged from 71.00 to 100.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Diagnostics & Research company?
A good GF Score depends on the Medical Diagnostics & Research industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on IDEXX Laboratories and its competitors. IDEXX Laboratories's current GF Score is 96, which is near median its own 10-year median of 93.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
IDEXX Laboratories (XTER:IX1) has a current GF Score of 96. The stock's GF Value™ is €561.51, compared to a current price of €488.90 — trading 12.9% below its estimated fair value. The current GF Score is 96, which is near median its 10-year median of 93.00. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For IDEXX Laboratories (XTER:IX1), the current GF Score is 96 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (XTER:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €488.90 is trading 12.9% below its estimated GF Value™ of €561.51.
Key valuation signals for XTER:IX1:
GF Score: 96 (near median its 10-year median of 93.00)
GF Value™: €561.51 vs. price of €488.90 (12.9% below fair value)
No single metric tells the full story. See the XTER:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for XTER:IX1
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:IX1 has been successfully added to your 